The perimenopause is a stage of life when a woman has low fertility but still requires contraception. It is also a peak age for menstrual dysfunction and a time when menopausal symptoms may commence. All these factors impact on contraceptive choice. Combined oral contraception can be continued until the age of 50 years in women who are low risk and do not smoke. Progestogen-only methods have advantages for women who have risk factors for cardiovascular disease. An intrauterine device may exacerbate menstrual problems at this stage but the levonorgestrel releasing intrauterine system is highly effective in controlling perimenopausal menstrual dysfunction. Women should receive accurate individualised advice on how the risks and benefits of contraceptive methods relate to them and on when contraception can be safely discontinued. Hormone replacement therapy is not reliably contraceptive and women should be advised to continue with a contraceptive method until they have reached natural sterility.
. RuessMLKlineJSantosR. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol1996; 174: 624–627.
5.
. The Guinness book of Records. Guinness Media Inc, ed. Guinness World Records Limited, London, Bantam books. 2000.
6.
. Office for National Statistics. Population trends. The Stationary Office. London. Spring 1997; 87: 17.
7.
. MaroulisGB. Effect of ageing on fertility and pregnancy. Semin Reprod Endocrinol1991; 3: 165–175.
8.
. SpellacyWNMillerSLWinegarA.Pregnancy after 40 years of age. Obstet Gynecol1986; 83: 452–454.
9.
. JohnsonAWadsworthJ.Heterosexual practices. In WellingsKFieldJJohnsonA, eds. Sexual behaviour in Britain. The national survey of sexual attitudes and lifestyles, pp 133–177. London: Penguin Books, 1995.
10.
. BancroftJ.Sexuality and Family Planning. In GlasierAGebbieA, eds. Handbook of Family Planning, pp 313–334. Edinburgh: Churchill Livingstone, 2000.
11.
. Schering Healthcare Consumer Study 1999 (data on file – personal communication).
12.
. ToulemonLLeridonH.Contraceptive practice and trends in France. Family Planning Perspectives1998; 30: 114–120.
13.
. OddensBJVisserAPVemerHM. Contraceptive use and attitudes in Great Britain. Contraception1994; 49: 73–86.
14.
. BeralVHermonCKayC. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from the Royal College of General Practitioners' oral contraception study. BMJ1999; 318: 96–100.
15.
. World Health Organization.Improving access to quality care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. WHO/FRH/FPP/96.9. Geneva, 1996.
16.
. World Health Organisation. Cardiovascular disease and use of oral and injectable progestogen-only contraceptive and combined injectable contraceptives. Results of an international multicentre, case-control study. Contraception1998; 57: 315–324.
17.
. JickHKayeJAVasilakis-ScaramozzaCJickS.Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ2000; 321: 1190–1195.
18.
. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and Hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100, 239 women without breast cancer from 543 epidemiological studies. Lancet1996; 347: 1717–1727.
19.
. MarchbanksPAMcDonaldJAWilsonHG. Oral contraceptives and risk of breast cancer. N Engl J Med2002; 346: 2025–2032.
20.
. SmithJSGreenJBerrington de GonzalezA. Cervical cancer and use of hormonal contraceptives; a systemic review. Lancet2003; 361: 1159–1163.
21.
. FrancheschiS.Oral contraceptive use and risk of cancer of the ovary and corpus uteri. In HannafordPCWebbAMC, eds. Evidence-guided prescribing of the pill. pp 135–144. Camforth: Parthenon Publishing Group, 1996
22.
. MartinezMEGrondsteinFGiovannucciE. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev1997; 6: 1–5.
23.
. BrintonLAVesseyMPFlavelR. Risk factors for benign breast disease. Am J Epidemiol1981; 113: 203–214.
24.
. LanesSFBirmannBWalkerAM. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol1992; 166: 956–961.
25.
. LarssonGMilsonILindstedtGRyboG.The influence of low-dose combined oral contraception on menstrual blood loss and iron status. Contraception1992; 46: 327–334.
26.
. VesseyMPainterRMantJ.Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: findings in a large cohort study. Br J Fam Plann1996; 22: 166–169.
27.
. KunhongWBorgattaLStubblefieldP.Low dose oral contraceptives and bone mineral density: an evidence base analysis. Contraception2000; 61: 77–82.
28.
. VesseyMPLawlessMYeatsDMcPhersonK.Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann1985; 10: 117–121.
29.
. RiceCFKillickSRDiebenTCoelingh BenninkH.A comparison of the inhibition achieved by desogestrel 75 μg and levonorgestrel 30 μg daily. Hum Reprod1999; 14: 982–985.
30.
. VesseyMPainterR.Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann and Reprod Health Care2001; 27: 90–91.
31.
. TangOSTangGYipP. Long term depot-medroxyprogesterone acetate and bone mineral density. Contraception1999; 59: 25–29.
32.
. Orr-WalkerBJEvansMCAmesRW. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. Clin Endocrinol1998; 49: 615–618.
33.
. CundyTCornishJEvansMC. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ1994; 308: 247–248.
34.
. EdwardsJEMooreA.Implanon – a review of clinical studies. Br J Fam Plann1999; 24(Suppl 4): 3–16.
. ChiI-C.What we have learned from recent IUD studies: a researcher's perspective. Contraception1993; 48: 81–108.
37.
. Kazuh-NovakMAndoleskL.IUD use after 40 years of age. Adv Contracept1988; 4: 85–89.
38.
. TacchiD.Long term use of copper intra-uterine devices. Lancet1991; 336: 182.
39.
. AnderssonKRyboG.Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol1990; 97: 690–694.
40.
. HurskainenRTeperiJRissanenP. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet2001; 357: 273–277.
41.
. AnderssonKMattssonL-ARyboG.Intrauterine release of levonorgestrel; a new way of adding progestogen in hormone replacement therapy. Am J Obstet Gynecol1992; 79: 963–967.
42.
. RadoskoskiTLahtiEKauppilaA. Transdermal oestrogen with a levonorgestrel-releasing intrauterine device for climacteric symptoms. Am J Obstet Gynecol1995; 172: 114–119.
43.
. RiphagenFE. Intrauterine application of progestins in hormone replacement therapy; a review. Climacteric2000; 3: 199–212.
44.
. RadoskoskiTTapanainenJTomasE. Intrauterine 10ug and 20ug levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol2002; 109: 136–144.
45.
. BoundsW.Contraceptive efficacy of the diaphragm and cervical caps use in conjunction with a spermicide. A fresh look at the evidence. Br J Fam Plann1994; 20: 84–87.
46.
. HillisSDMarchbanksPATylorLRPetersonHB. Poststerilization regret: findings from the United States review of sterilisation. Obstet Gynecol1999; 93: 889–895.
47.
. GebbieA.Menopause. In GlasierAGebbieA, eds. Handbook of family planning and reproductive health care, pp 371–394, Edinburgh: Churchill Livingstone, 2000.
48.
. CastracaneVDGimpelRGoldzieherJW. When is it safe to switch from oral contraceptives to hormonal replacement therapy?Contraception1995; 52: 371–376.
49.
. GebbieAGlasierASweetingV.Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception1995; 52: 221–222.
